CalciMedica is a clinical-stage biopharmaceutical company developing intravenous Auxora for hospital-based use and oral CM5480 for chronic treatment.
Auxora for hospital-based intravenous treatment and CM5480 for chronic oral treatment.
A focused strategy designed to generate human proof-of-concept data with Auxora and advance CM5480 toward clinical development.
A Phase 2b clinical signal and FDA alignment on the next study's design.
Built on CRAC channel research and decades of drug development experience.
CalciMedica's management team brings experience in foundational CRAC channel biology, clinical development, biotechnology operations, business development, capital formation, and public-company leadership.
Chief Executive Officer
Dr. Leheny has more than 30 years of life sciences experience spanning scientific research, biotechnology equity research, and venture investing. Prior to CalciMedica, she led biotechnology research at Lehman Brothers and UBS Warburg and co-founded Valence Life Sciences.
President & Chief Operating Officer
Mr. Dunn has 35 years of pharmaceutical and biotechnology experience across corporate development, business development, and operations. He has held senior leadership roles at public and private life sciences companies including Biocept, Monogram Biosciences, and Aurora Biosciences.
Chief Medical Officer
Dr. Hebbar has more than 15 years of clinical development and product-development experience across therapeutics and diagnostics, following 12 years in clinical practice in nephrology, hypertension, transplantation, and critical care. His industry experience includes Reata Pharmaceuticals, Abbott, Thrasos Innovation, and Oncimmune.
Chief Scientific Officer
Dr. Stauderman has more than 30 years of pharmaceutical and biotechnology research experience focused on intracellular calcium signaling. A CalciMedica co-founder, he contributed to foundational work identifying STIM1 as a key regulator of CRAC channels.
Chief Financial Officer
Mr. Bardin has more than 10 years of life sciences experience across finance, operations, and corporate development. Prior to CalciMedica, he served as Chief Financial Officer of atai Life Sciences and held finance leadership roles at BridgeBio Pharma and Myovant Sciences.
Chief Business Officer & Vice Chairman of the Board
Mr. Roberts has 30 years of experience in life sciences finance and investing and has completed hundreds of financings and merger transactions. He previously led healthcare and life sciences investment banking teams at Lehman Brothers and UBS and co-founded Valence Life Sciences.
General Counsel
Mr. Dunn has more than 25 years of corporate legal experience in the life sciences industry. He previously held senior legal and venture roles at Biogen Idec and served as Senior Vice President and General Counsel of IDEC Pharmaceuticals.
CalciMedica's Board of Directors brings experience in clinical development, biotechnology finance, and public-company governance.
Chairman of the Board
Director
Director
Director
Director
Director
Director
Learn more about employment opportunities and how to contact the company.
Information regarding CalciMedica's Board of Directors, committees, governance documents, and related policies is available through the investor relations site.
